Avanir
This article was originally published in The Tan Sheet
Executive Summary
Firm files New Drug Submission with the Canadian Therapeutic Products Programme (TPP) for OTC sale of docosanol 10% cream. Avanir estimates approximately 15 months for TPP review, with marketing authorization possible in the first quarter 2002. In July, Avanir's Abreva docosanol 10% cream received FDA clearance as an OTC cold sore treatment (1"The Tan Sheet" July 31, p. 3). SmithKline Beecham holds the marketing rights in the U.S. and Canada